Stockreport

Recent 4.1% pullback isn't enough to hurt long-term Ultragenyx Pharmaceutical (NASDAQ:RARE) shareholders, they're still up 70% over 1 year [Yahoo! Finance]

Ultragenyx Pharmaceutical Inc.  (RARE) 
Last ultragenyx pharmaceutical inc. earnings: 2/13 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.ultragenyx.com/investor-relations
PDF Ultragenyx Pharmaceutical Inc. NASDAQ:RARE ) share price is 70% higher than it was a year ago, much better than the market return of around 37% (not including dividends [Read more]